Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci, vol.98, pp.10869-10874, 2001. ,
Molecular portraits of human breast tumours, Nature, vol.406, pp.747-752, 2000. ,
A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1), J Exp Med, vol.184, pp.1101-1109, 1996. ,
Molecular cloning and characterization of a murine pre-B-cell growth-stimulating factor/ stromal cell-derived factor 1 receptor, a murine homolog of the human immunodeficiency virus 1 entry coreceptor fusin, Proc Natl Acad Sci, vol.93, pp.14726-14729, 1996. ,
Transgene expression study of CXCR4 active mutants. Potential prospects in up-modulation of homing and engraftment efficiency of hematopoietic stem/progenitor cells, Cell Adhes Migr, vol.8, pp.384-388, 2014. ,
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development, Nature, vol.393, pp.595-599, 1998. ,
Chemokine receptors in human endothelial cells. Functional expression of CXCR4 and its transcriptional regulation by inflammatory cytokines, J Biol Chem, vol.273, pp.4282-4287, 1998. ,
Detection and delineation of CXCR-4 (fusin) as an entry and fusion cofactor for T-tropic [correction of T cell-tropic] HIV-1 by three different monoclonal antibodies, J Immunol Baltim Md, vol.160, pp.180-188, 19501998. ,
Functional expression of chemokine receptor CXCR4 on human epithelial cells, Immunology, vol.98, pp.36-41, 1999. ,
The significance of cancer cell expression of the chemokine receptor CXCR4, Semin Cancer Biol, vol.14, pp.171-179, 2004. ,
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment, Blood, vol.107, pp.1761-1767, 2006. ,
Chemokines and cancer, Int Cancer, vol.119, pp.2026-2029, 2006. ,
The impact of chemokine receptor CXCR4 on breast cancer prognosis: a meta-analysis, Cancer Epidemiol, vol.37, pp.725-731, 2013. ,
Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis, BMC Cancer, vol.14, p.49, 2014. ,
The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo, PloS One, vol.8, p.58426, 2013. ,
CXCR4 regulates growth of both primary and metastatic breast cancer, Cancer Res, vol.64, pp.8604-8612, 2004. ,
Silencing of CXCR4 sensitizes triplenegative breast cancer cells to cisplatin, Oncotarget, vol.6, pp.1020-1030, 2015. ,
Involvement of chemokine receptors in breast cancer metastasis, Nature, vol.410, pp.50-56, 2001. ,
A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer, J Surg Res, vol.155, pp.231-236, 2009. ,
Oxidative stress promotes myofibroblast differentiation and tumour spreading, EMBO Mol Med, vol.2, pp.211-230, 2010. ,
Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis, FASEB J Off Publ Fed Am Soc Exp Biol, vol.18, pp.1240-1242, 2004. ,
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion, Cell, vol.121, pp.335-348, 2005. ,
Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer, Clin Exp Metastasis, vol.27, pp.233-240, 2010. ,
The role of reactive oxygen species and metabolism on cancer cells and their microenvironment, Semin Cancer Biol, vol.25, pp.23-32, 2014. ,
CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization, Curr Pharm Des, vol.16, pp.3903-3920, 2010. ,
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study, Breast Cancer Res Treat, vol.97, pp.275-283, 2006. ,
CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model, Int J Cancer, vol.129, pp.225-232, 2011. ,
Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA, Biochem Biophys Res Commun, vol.363, pp.542-546, 2007. ,
A new model of patient tumor-derived breast cancer xenograft for preclinical assays, Clin Cancer Res Off J Am Assoc Cancer Res, vol.13, pp.3989-3998, 2007. ,
Molecular profiling of patient-derived breast cancer xenografts, Breast Cancer Res, vol.14, p.11, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00675301
Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists, J Biol Chem, vol.278, pp.47136-47144, 2003. ,
A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists, J Biol Chem, vol.277, pp.24515-24521, 2002. ,
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer, Cancer Res, vol.67, pp.11821-11829, 2007. ,
T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer, FEBS Lett, vol.550, pp.79-83, 2003. ,
Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk, Mol Cancer, vol.9, p.295, 2010. ,
A role of CXC chemokine ligand 12/stromal cell-derived factor-1/pre-B cell growth stimulating factor and its receptor CXCR4 in fetal and adult T cell development in vivo, J Immunol Baltim Md, vol.170, pp.4649-4655, 1950. ,
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4, Science, vol.283, pp.845-848, 1999. ,
CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia, FASEB J Off Publ Fed Am Soc Exp Biol, vol.20, pp.1913-1915, 2006. ,
Stromal-derived factor 1 and matrix metalloproteinase 9 levels in bone marrow and peripheral blood of patients mobilized by granulocyte colony-stimulating factor and chemotherapy. Relationship with mobilizing capacity of haematopoietic progenitor cells, Br J Haematol, vol.122, pp.918-926, 2003. ,
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist, J Exp Med, vol.201, pp.1307-1318, 2005. ,
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, pp.4265-4274, 2005. ,
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, vol.344, pp.783-792, 2001. ,
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer, Cancer Cell, vol.12, pp.395-402, 2007. ,
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer, Oncotarget, vol.5, pp.5934-5949, 2014. ,
p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer, Clin Cancer Res Off J Am Assoc Cancer Res, vol.12, pp.424-431, 2006. ,
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, pp.2750-2767, 2011. ,
Molecular characterization of the tumor microenvironment in breast cancer, Cancer Cell, vol.6, pp.17-32, 2004. ,
CXCR4 is expressed in ductal carcinoma in situ of the breast and in atypical ductal hyperplasia, Breast Cancer Res Treat, vol.84, pp.247-250, 2004. ,
Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer, Breast Cancer Res, vol.7, pp.402-410, 2005. ,
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation, Cancer Res, vol.65, pp.6493-6497, 2005. ,
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis, Cancer Cell, vol.6, pp.459-469, 2004. ,
Silencing of CXCR4 blocks breast cancer metastasis, Cancer Res, vol.65, pp.967-971, 2005. ,
Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast, Tumour Biol J Int Soc Oncodevelopmental Biol Med, vol.25, pp.290-295, 2004. ,
Microenvironmental regulation of metastasis, Nat Rev Cancer, vol.9, pp.239-252, 2009. ,
Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers, Autophagy, vol.10, pp.2122-2142, 2014. ,
MAP3K8/ TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in highgrade serous ovarian carcinomas, Nat Commun, vol.6, p.8583, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02437815